Company Overview of Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. develops drugs for the treatment of a range of debilitating neurogenic disorders. It develops P2X3, a purinergic receptor that plays a key role in the sensitization of nerves; AF-219, a selective P2X3 antagonist for the treatment of pathologic cough; and P2X3 antagonist that blocks P2X3 in the carotid body. It offers programs in the areas of respiratory diseases, resistant hypertension, P2X3 biology, cardiovascular diseases, and chronic pain and other indications; and clinical trials. The company was founded in 2009 and is based in San Mateo, California. As of July 27, 2016, Afferent Pharmaceuticals, Inc. operates as a subsidiary of Merck & Co. Inc.
2929 Campus Drive
San Mateo, CA 94403
Founded in 2009
Key Executives for Afferent Pharmaceuticals, Inc.
Chief Executive Officer and Director
Co-Founder and Chief Scientific Officer
Vice President of Clinical Operations
Compensation as of Fiscal Year 2016.
Afferent Pharmaceuticals, Inc. Key Developments
Afferent Pharmaceuticals, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-12-2016 11:20 AM
Mar 24 16
Afferent Pharmaceuticals, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-12-2016 11:20 AM. Venue: The Westin NY Grand Central Hotel, 212 East 42nd Street, New York, NY 10017, United States.
Afferent Pharmaceuticals, Inc. Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial
Dec 8 15
Afferent Pharmaceuticals, Inc. announced initiation of the company’s Phase 1 trial of AF-130, a selective and differentiated P2X3 antagonist. Afferent’s Phase 1, double-blind, randomized, placebo-controlled trial is designed to assess the safety, tolerability and pharmacokinetics of single ascending doses and, in a second cohort, multiple ascending doses of AF-130 administered to healthy subjects. Pending the progress of the Phase 1 trial, Afferent intends to evaluate AF-130 in multiple conditions, including treatment-resistant hypertension, and potentially in heart failure, migraine and visceral pain. The goal of treatment with a P2X3 inhibitor is to restore normal physiological function by blocking ATP activation of P2X3 channels that otherwise leads to sensitization of certain nerves and pathological signs and symptoms. Afferent’s lead product, AF-219, is currently being developed for the treatment of pathologic cough, including chronic cough, and cough in idiopathic pulmonary fibrosis (IPF) patients. Afferent’s clinical candidates – AF-219 and AF-130 – are orally available, first-in-class compounds that selectively block P2X3 receptors. P2X3 receptors play a key role in the sensitization of certain sensory nerves, notably C-fiber afferents. These nerves become activated and sensitized under pathological conditions mediated by a common cellular signal, ATP, when it is released in high concentrations due to cellular distress following injury or infection. Afferent’s compounds selectively block ATP activation of P2X3 channels, reducing a range of sensory signs and symptoms. P2X3 receptor-mediated sensitization has been implicated in inflammatory, visceral and neuropathic pain states, as well as airways hyperreactivity, treatment-resistant hypertension, heart failure, migraine, itch and cancer pain.
Afferent Pharmaceuticals Announces Executive Appointments
Nov 19 15
Afferent Pharmaceuticals announced the appointments of Prabha N. Ibrahim, Ph.D., as chief technology officer and Michelle Carpenter, J.D., RAC, as vice president of regulatory affairs and project management. Dr. Ibrahim will be responsible for directing manufacturing of drug supplies, from initial scale up to registration and commercial supplies, as well as management of Afferent’s intellectual property portfolio, while Ms. Carpenter will be responsible for global regulatory affairs as well as project management for the company’s development stage programs. Dr. Ibrahim brings more than 23 years of experience in drug discovery and development, having served in a number of senior leadership positions at Plexxikon Inc., most recently as senior vice president of chemistry and non-clinical development. Ms. Carpenter brings 25 years of biopharmaceutical experience in regulatory strategy and operations in support of drug development and commercialization. Prior to joining Afferent, Ms. Carpenter held senior positions at Acucela.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 9, 2016